Dynavax Technologies Corporation has immunised the first of over 2,000 subjects enrolled in its Phase III clinical study of investigational adult hepatitis B vaccine HEPLISAV.

The immunisation will lead to a one-year follow-up on the subjects, completing the study in May 2011.

Dynavax is aiming at a Biologics License Application submission in the second half of next year.

The vaccine candidate will undergo two Phase III studies to seek regulatory approvals in Canada, Europe and the US.